Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors

Joanna Huszno; Zofia Kolosza; Jolanta Mrochem-Kwarciak; Ewa Grzybowska

doi:10.5114/aoms/147736

Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors

Arch Med Sci. 2022 Apr 14;18(3):800-804. doi: 10.5114/aoms/147736. eCollection 2022.

Authors

Joanna Huszno¹, Zofia Kolosza², Jolanta Mrochem-Kwarciak³, Ewa Grzybowska⁴

Affiliations

¹ Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
² Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
³ Analytics and Clinical Biochemistry Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
⁴ Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.

Abstract

Introduction: The objective of the present study was to characterize > 65-year-old patients with breast cancer according to clinicopathological, molecular and laboratory factors.

Methods: A total of 723 breast cancer patients, who had been diagnosed and treated during 2005-2019, were retrospectively reviewed. Patients > 65 years of age (92 patients) were compared with < 50-year-old women (306 patients). We analyzed 398 women from 723 patients.

Results: Overall survival analysis was conducted for both groups, separately and combined. Patients with BC aged > 65 years were characterized by G1-2, higher lymphocyte values, lower platelet (PLT) counts and lower NLR or PLR values than patients < 50 years of age.

Conclusions: Age > 65 years is a negative prognostic factor independent of other factors.

Keywords: BRCA; breast cancer; checkpoint kinase 2; neutrophil-to-lymphocyte ratio; nucleotide binding oligomerization domain containing 2 mutation; platelet; platelet-to-lymphocyte ratio.